MCP
NVO

Moab Capital Partners’s Novo Nordisk NVO Stock Holding History

Moab Capital Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-86,084
Closed -$2.23M – 24
2019
Q3 		$2.23M Buy
+86,084
New +$2.18M 0.85% 21

Other funds holding NVO

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return

Moab Capital Partners's NVO Position: Q4 2019 in Review

Moab Capital Partners sold out of Novo Nordisk (NVO) in Q4 2019, closing a stake of 86,084 shares — an estimated $2.23M sold.

Moab Capital Partners first reported a position in NVO in Q3 2019 and held it in 1 quarter. The position peaked at $2.23M in Q3 2019. 640 funds tracked by Wall St. Rank hold NVO as of Q4 2019.

  • Moab Capital Partners reported no remaining Novo Nordisk position as of Q4 2019 after selling out during the quarter.
  • Moab Capital Partners sold 86,084 Novo Nordisk shares in Q4 2019, an estimated $2.23M.
  • Moab Capital Partners first reported a position in Novo Nordisk in Q3 2019 and held it in 1 quarter.
  • Moab Capital Partners's Novo Nordisk position peaked at $2.23M in Q3 2019.
  • 640 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2019.

Based on Moab Capital Partners's 13F filing for Q4 2019, filed 14 Feb 2020.